Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

Study limitation reported by the research below: “Protocol changed mid-trial from double-blind placebo to open-label observation, which could introduce performance or detection bias.”